FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311817912> ?p ?o ?g. }

• W4311817912 endingPage "100452" @default.
• W4311817912 startingPage "100452" @default.
• W4311817912 abstract "Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be promising in the treatment of coronavirus disease 2019. The active antiviral component nirmatrelvir in Paxlovid is co-formulated with ritonavir, a strong cytochrome P450 (CYP) 3A4 inhibitor. Many oral targeted therapies indicated for lung cancer are known substrates of CYP 3A4, and concurrent use with Paxlovid may lead to potential drug-drug interaction (DDI). The purpose of this review is to evaluate the potential DDI between targeted therapies and supportive care for lung cancer and ritonavir-boosted nirmatrelvir.Drug database search in PubMed and the Food and Drug Administration was conducted to identify pharmacokinetic data on oral tyrosine kinase inhibitors (TKIs) used in NSCLC, both Food and Drug Administration approved and those in development. Metabolism pathways for various TKIs are extracted, and the impact of TKI area under the curves and maximum concentration by strong CYP 3A4 inducers and inhibitors is summarized. The most common toxicities and supportive care medications for the TKI were identified.Among EGFR and exon 20 insertion inhibitors, afatinib is least likely to be affected by CYP 3A4, followed by dacomitinib and osimertinib. Among ALK inhibitors, alectinib is the least susceptible to CYP 3A4. ROS1 inhibitors are affected by CYP 3A4 inhibition with the exception of crizotinib. Among MET inhibitors, capmatinib is substantially affected by CYP 3A4 inhibition. Drug exposure of RET inhibitors is expected to increase with CYP 3A4 inhibition, with selpercatinib being the least affected. Certain supportive care medications for lung cancer TKI may have relevant DDIs.The clinical impact of the DDI between lung cancer TKI and ritonavir-boosted nirmatrelvir varies largely on the basis of the susceptibility of CYP 3A4 inhibition caused by the antiviral. Close monitoring and medication adjustments (i.e., dose changes or alternative coronavirus disease 2019 therapy) can be used to overcome DDI to ensure patient safety." @default.
• W4311817912 created "2022-12-29" @default.
• W4311817912 creator A5006315455 @default.
• W4311817912 creator A5028540697 @default.
• W4311817912 creator A5032642926 @default.
• W4311817912 creator A5060083195 @default.
• W4311817912 creator A5060981830 @default.
• W4311817912 date "2023-02-01" @default.
• W4311817912 modified "2023-10-05" @default.
• W4311817912 title "Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer" @default.
• W4311817912 cites W1972631809 @default.
• W4311817912 cites W2093459813 @default.
• W4311817912 cites W2097568312 @default.
• W4311817912 cites W2528424364 @default.
• W4311817912 cites W2775590462 @default.
• W4311817912 cites W2795758525 @default.
• W4311817912 cites W3192713004 @default.
• W4311817912 cites W3214615572 @default.
• W4311817912 cites W4200051875 @default.
• W4311817912 cites W4220830372 @default.
• W4311817912 cites W4254503311 @default.
• W4311817912 cites W4285037459 @default.
• W4311817912 doi "https://doi.org/10.1016/j.jtocrr.2022.100452" @default.
• W4311817912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36568522" @default.
• W4311817912 hasPublicationYear "2023" @default.
• W4311817912 type Work @default.
• W4311817912 citedByCount "1" @default.
• W4311817912 countsByYear W43118179122023 @default.
• W4311817912 crossrefType "journal-article" @default.
• W4311817912 hasAuthorship W4311817912A5006315455 @default.
• W4311817912 hasAuthorship W4311817912A5028540697 @default.
• W4311817912 hasAuthorship W4311817912A5032642926 @default.
• W4311817912 hasAuthorship W4311817912A5060083195 @default.
• W4311817912 hasAuthorship W4311817912A5060981830 @default.
• W4311817912 hasBestOaLocation W43118179121 @default.
• W4311817912 hasConcept C109650736 @default.
• W4311817912 hasConcept C112705442 @default.
• W4311817912 hasConcept C121608353 @default.
• W4311817912 hasConcept C126322002 @default.
• W4311817912 hasConcept C142462285 @default.
• W4311817912 hasConcept C143998085 @default.
• W4311817912 hasConcept C203014093 @default.
• W4311817912 hasConcept C2776232967 @default.
• W4311817912 hasConcept C2776256026 @default.
• W4311817912 hasConcept C2778087573 @default.
• W4311817912 hasConcept C2779298103 @default.
• W4311817912 hasConcept C2779422266 @default.
• W4311817912 hasConcept C2779438470 @default.
• W4311817912 hasConcept C2780035454 @default.
• W4311817912 hasConcept C2993143319 @default.
• W4311817912 hasConcept C3013748606 @default.
• W4311817912 hasConcept C526171541 @default.
• W4311817912 hasConcept C62231903 @default.
• W4311817912 hasConcept C71924100 @default.
• W4311817912 hasConcept C98274493 @default.
• W4311817912 hasConceptScore W4311817912C109650736 @default.
• W4311817912 hasConceptScore W4311817912C112705442 @default.
• W4311817912 hasConceptScore W4311817912C121608353 @default.
• W4311817912 hasConceptScore W4311817912C126322002 @default.
• W4311817912 hasConceptScore W4311817912C142462285 @default.
• W4311817912 hasConceptScore W4311817912C143998085 @default.
• W4311817912 hasConceptScore W4311817912C203014093 @default.
• W4311817912 hasConceptScore W4311817912C2776232967 @default.
• W4311817912 hasConceptScore W4311817912C2776256026 @default.
• W4311817912 hasConceptScore W4311817912C2778087573 @default.
• W4311817912 hasConceptScore W4311817912C2779298103 @default.
• W4311817912 hasConceptScore W4311817912C2779422266 @default.
• W4311817912 hasConceptScore W4311817912C2779438470 @default.
• W4311817912 hasConceptScore W4311817912C2780035454 @default.
• W4311817912 hasConceptScore W4311817912C2993143319 @default.
• W4311817912 hasConceptScore W4311817912C3013748606 @default.
• W4311817912 hasConceptScore W4311817912C526171541 @default.
• W4311817912 hasConceptScore W4311817912C62231903 @default.
• W4311817912 hasConceptScore W4311817912C71924100 @default.
• W4311817912 hasConceptScore W4311817912C98274493 @default.
• W4311817912 hasIssue "2" @default.
• W4311817912 hasLocation W43118179121 @default.
• W4311817912 hasLocation W43118179122 @default.
• W4311817912 hasLocation W43118179123 @default.
• W4311817912 hasLocation W43118179124 @default.
• W4311817912 hasOpenAccess W4311817912 @default.
• W4311817912 hasPrimaryLocation W43118179121 @default.
• W4311817912 hasRelatedWork W1249055141 @default.
• W4311817912 hasRelatedWork W1803443763 @default.
• W4311817912 hasRelatedWork W1939210775 @default.
• W4311817912 hasRelatedWork W2036206567 @default.
• W4311817912 hasRelatedWork W2042683997 @default.
• W4311817912 hasRelatedWork W2076136110 @default.
• W4311817912 hasRelatedWork W2137448351 @default.
• W4311817912 hasRelatedWork W4205993769 @default.
• W4311817912 hasRelatedWork W4220830372 @default.
• W4311817912 hasRelatedWork W4311817912 @default.
• W4311817912 hasVolume "4" @default.
• W4311817912 isParatext "false" @default.
• W4311817912 isRetracted "false" @default.
• W4311817912 workType "article" @default.